Danaher Corporation (NYSE:DHR) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Danaher has a “Moderate Buy” consensus rating from 25 analysts: 18 rate it a buy, two a strong buy and five a hold. The average 12-month price target is $228.91, above the reported share price of $203.44.
• Recent analyst views are mixed, with price targets ranging from $195 at Wells Fargo to $250 at UBS. Piper Sandler initiated coverage with a neutral rating and a $200 target, while DZ Bank and UBS issued buy ratings.
• Danaher exceeded quarterly expectations, reporting adjusted earnings of $1.94 per share versus the $1.85 consensus and revenue of $6.26 billion, up 5.5% year over year. Institutional investors own approximately 79.05% of the company’s shares.

Danaher Corporation (NYSE:DHR - Get Free Report) has received a consensus rating of "Moderate Buy" from the twenty-five analysts that are presently covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $228.9130.

DHR has been the topic of several recent research reports. Piper Sandler began coverage on shares of Danaher in a research note on Thursday, June 11th. They set a "neutral" rating and a $200.00 target price on the stock. DZ Bank began coverage on shares of Danaher in a research report on Wednesday, June 3rd. They issued a "buy" rating and a $210.00 target price for the company. Wells Fargo & Company decreased their price target on shares of Danaher from $212.00 to $195.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 22nd. HSBC lowered their price target on shares of Danaher from $270.00 to $230.00 and set a "buy" rating on the stock in a research report on Wednesday, June 3rd. Finally, UBS Group initiated coverage on shares of Danaher in a research note on Wednesday, September 9th. They set a "buy" rating and a $250.00 price objective for the company.

Danaher Price Performance

NYSE:DHR opened at $203.44 on Tuesday. The stock has a 50 day moving average of $202.85 and a two-hundred day moving average of $191.91. Danaher has a 12 month low of $160.93 and a 12 month high of $242.80. The firm has a market cap of $143.01 billion, a P/E ratio of 36.13, a price-to-earnings-growth ratio of 2.49 and a beta of 0.78. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter last year, the business posted $0.77 earnings per share. The business's quarterly revenue was up 5.5% compared to the same quarter last year. On average, analysts expect that Danaher will post 8.53 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Danaher

A number of large investors have recently made changes to their positions in DHR. High Note Wealth LLC grew its position in shares of Danaher by 19.2% in the fourth quarter. High Note Wealth LLC now owns 292 shares of the conglomerate's stock valued at $67,000 after purchasing an additional 47 shares during the period. First Command Advisory Services Inc. increased its stake in Danaher by 4.4% in the fourth quarter. First Command Advisory Services Inc. now owns 1,104 shares of the conglomerate's stock valued at $253,000 after purchasing an additional 47 shares during the last quarter. Gabelli Funds LLC lifted its position in Danaher by 0.3% during the fourth quarter. Gabelli Funds LLC now owns 18,981 shares of the conglomerate's stock worth $4,345,000 after buying an additional 50 shares during the period. Studio Investment Management LLC lifted its position in Danaher by 3.3% during the second quarter. Studio Investment Management LLC now owns 1,581 shares of the conglomerate's stock worth $302,000 after buying an additional 51 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd boosted its stake in Danaher by 71.6% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate's stock worth $29,000 after buying an additional 53 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Company Profile

Danaher Corporation NYSE: DHR is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its businesses support pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers.

The company's portfolio includes bioprocessing technologies, laboratory instruments, consumables, reagents and software. Key businesses include Cytiva, which provides biomanufacturing solutions; Beckman Coulter, which supplies laboratory diagnostics and automation systems; Leica Biosystems, which develops pathology products; and IDT, which provides genomic and nucleic acid products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.